Literature DB >> 12393805

New insights into the molecular basis of progressive myoclonus epilepsy: a multiprotein complex with cystatin B.

Rossella Di Giaimo1, Massimo Riccio, Spartaco Santi, Cesira Galeotti, Davide C Ambrosetti, Marialuisa Melli.   

Abstract

Cystatin B is an anti-proteolytic polypeptide implicated in progressive myoclonus epilepsy (EPM1), a degenerative disease of the central nervous system. The knock-out mouse model of the disease shows apoptosis of the cerebellar granule cells. We have identified five recombinant proteins interacting with cystatin B and none of them is a protease. We show that three of these proteins (RACK-1, beta-spectrin and NF-L) co-immunoprecipitate with cystatin B in rat cerebellum. Confocal immunofluorescence analysis shows that the same proteins are present in the granule cells of developing cerebellum, as well as in Purkinje cells of adult rat cerebellum. We propose that a cystatin B multiprotein complex has a specific cerebellar function and that the loss of this function might contribute to the disease in EPM1 patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393805     DOI: 10.1093/hmg/11.23.2941

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  21 in total

1.  Differences in aggregation properties of three site-specific mutants of recombinant human stefin B.

Authors:  Manca Kenig; Selma Berbić; Aida Krijestorac; Louise Kroon-Zitko; Magda Tusek; Marusa Pompe-Novak; Eva Zerovnik
Journal:  Protein Sci       Date:  2004-01       Impact factor: 6.725

2.  In vitro study of stability and amyloid-fibril formation of two mutants of human stefin B (cystatin B) occurring in patients with EPM1.

Authors:  Sabina Rabzelj; Vito Turk; Eva Zerovnik
Journal:  Protein Sci       Date:  2005-09-09       Impact factor: 6.725

3.  Interaction between oligomers of stefin B and amyloid-beta in vitro and in cells.

Authors:  Katja Skerget; Ajda Taler-Vercic; Andrej Bavdek; Vesna Hodnik; Slavko Ceru; Magda Tusek-Znidaric; Tiina Kumm; Didier Pitsi; Marusa Pompe-Novak; Peep Palumaa; Salvador Soriano; Natasa Kopitar-Jerala; Vito Turk; Gregor Anderluh; Eva Zerovnik
Journal:  J Biol Chem       Date:  2009-12-02       Impact factor: 5.157

4.  Co-chaperoning by amyloid-forming proteins: cystatins vs. crystallins.

Authors:  Eva Žerovnik
Journal:  Eur Biophys J       Date:  2017-05-06       Impact factor: 1.733

5.  Implications of ER stress, the unfolded protein response, and pro- and anti-apoptotic protein fingerprints in human monocyte-derived dendritic cells treated with alcohol.

Authors:  Nawal M Boukli; Zainulabedin M Saiyed; Martha Ricaurte; José W Rodriguez; Eddy Ríos Olivares; Luis A Cubano; Madhavan P N Nair
Journal:  Alcohol Clin Exp Res       Date:  2010-09-22       Impact factor: 3.455

Review 6.  Molecular background of progressive myoclonus epilepsy.

Authors:  Anna-Elina Lehesjoki
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

7.  Cystatin B and SOD1: protein–protein interaction and possible relation to neurodegeneration.

Authors:  Lisa Ulbrich; Mauro Cozzolino; Elettra Sara Marini; Ilaria Amori; Antonella De Jaco; Maria Teresa Carrì; Gabriella Augusti-Tocco
Journal:  Cell Mol Neurobiol       Date:  2014-03       Impact factor: 5.046

8.  A Helicobacter pylori vacuolating toxin mutant that fails to oligomerize has a dominant negative phenotype.

Authors:  Christophe Genisset; Cesira L Galeotti; Pietro Lupetti; David Mercati; David A G Skibinski; Silvia Barone; Roberto Battistutta; Marina de Bernard; John L Telford
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

9.  A role for stefin B (cystatin B) in inflammation and endotoxemia.

Authors:  Katarina Maher; Barbara Jerič Kokelj; Miha Butinar; Georgy Mikhaylov; Mateja Manček-Keber; Veronika Stoka; Olga Vasiljeva; Boris Turk; Sergei A Grigoryev; Nataša Kopitar-Jerala
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

10.  Cystatins in immune system.

Authors:  Spela Magister; Janko Kos
Journal:  J Cancer       Date:  2012-12-20       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.